Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment
2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 19 February 2020Portfolio NewsDeciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock
18 February 2020Portfolio NewsEndotronix Announces Enrollment of the First Patients in the PROACTIVE-HF Pivotal Trial
10 February 2020Portfolio NewsAVROBIO Presents Positive Initial Data for its Investigational Cystinosis Program and plato™ Platform, as well as Positive Data Out to 32 Months for its Ongoing Investigational Fabry Program
10 February 2020Portfolio NewsArtios Pharma Strengthens Clinical Development Team with Senior Appointments- 5 February 2020Portfolio NewsSutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development
31 January 2020Portfolio NewsAmerican Well’s Amwell App Named Top Online Therapy Service by Wirecutter
23 January 2020Portfolio NewsBardy Diagnostics™ Announces Commercial Launch of the 14-Day Carnation Ambulatory Monitor (CAM) Patch
14 January 2020Portfolio NewsAdimab Extends Platform Partnership with Novo Nordisk- 13 January 2020Portfolio NewsBardy Diagnostics™ Names Ed Vertatschitsch as Chief Operating Officer and Announces Additions to the Leadership Team
9 January 2020Portfolio NewsCentauri Health Solutions Welcomes Abry Partners as New Lead Investor
9 January 2020SV NewsNew Year message from the Dementia Discovery Fund’s CEO
7 January 2020Portfolio NewsBicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle® Immuno-oncology Candidate, BT7401
